Cargando…

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia

A novel niosomal delivery system was designed and investigated for the targeted delivery of daunorubicin (DNR) against acute myeloid leukemia (AML). Anti-CD123 antibodies conjugated to Mal-PEG(2000)-DSPE were incorporated into normal niosomes (NS) via a post insertion method to afford antibody-modif...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Fu-rong, Jin, Hui, Wang, Yin, Chen, Chen, Li, Ming, Mao, Sheng-jun, Wang, Qiantao, Li, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244627/ https://www.ncbi.nlm.nih.gov/pubmed/28574300 http://dx.doi.org/10.1080/10717544.2017.1333170

Ejemplares similares

Daunorubicin-Loaded CdTe QDs Conjugated with Anti-CD123 mAbs: A Novel Delivery System for Myelodysplastic Syndromes Treatment
por: Guo, Dan, et al.
Publicado: (2020)

Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34(+ )acute myeloid leukemia cell lines and primary sorted CD34(+ )acute myeloid leukemia cells
por: Rao, Jia, et al.
Publicado: (2011)

A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia
por: Xu, Shilin, et al.
Publicado: (2021)

Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience
por: Tefferi, Ayalew, et al.
Publicado: (2022)

HMGA2 regulates acute myeloid leukemia progression and sensitivity to daunorubicin via Wnt/β-catenin signaling
por: Yang, Shuo, et al.
Publicado: (2019)

Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
por: Chen, Evan C, et al.
Publicado: (2018)

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
por: Lancet, Jeffrey E., et al.
Publicado: (2018)

First‐in‐human study of JNJ‐63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia
por: Boyiadzis, Michael, et al.
Publicado: (2023)

Niosomes, an alternative for liposomal delivery
por: Bartelds, Rianne, et al.
Publicado: (2018)

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
por: Ehninger, A, et al.
Publicado: (2014)

CD16(+)NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice
por: Williams, Brent A., et al.
Publicado: (2018)

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin
por: Han, Yixiang, et al.
Publicado: (2015)

CD123 targeting oncolytic adenoviruses suppress acute myeloid leukemia cell proliferation in vitro and in vivo
por: Li, G, et al.
Publicado: (2014)

Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
por: Arwanih, Elly Y, et al.
Publicado: (2022)

Casein-Based Nanoparticles: A Potential Tool for the Delivery of Daunorubicin in Acute Lymphocytic Leukemia
por: Zahariev, Nikolay, et al.
Publicado: (2023)

Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan
por: Ikezoe, Takayuki, et al.
Publicado: (2022)

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
por: Angelova, Evgeniya, et al.
Publicado: (2019)

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
por: Zhu, Yuanyuan, et al.
Publicado: (2023)

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Prognostic value of CD25/CD123 pattern of expression in acute myeloid leukemia patients with normal cytogenetic
por: Aref, Salah, et al.
Publicado: (2020)

Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia
por: Safaei, Akbar, et al.
Publicado: (2018)

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia
por: Sugita, Mayumi, et al.
Publicado: (2022)

CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
por: Pelosi, Elvira, et al.
Publicado: (2023)

TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling
por: Xiao, Yi, et al.
Publicado: (2020)

DeSUMOylation of chromatin-bound proteins limits the rapid transcriptional reprogramming induced by daunorubicin in acute myeloid leukemias
por: Boulanger, Mathias, et al.
Publicado: (2023)

Cyclodextrin modified niosomes to encapsulate hydrophilic compounds
por: Machado, Noelia D., et al.
Publicado: (2018)

Design and development of cefdinir niosomes for oral delivery
por: Bansal, Saurabh, et al.
Publicado: (2013)

Serratiopeptidase Niosomal Gel with Potential in Topical Delivery
por: Shinde, Ujwala A., et al.
Publicado: (2014)

Nanoarchitectonics of Multifunctional Niosomes for Advanced Drug Delivery
por: Momekova, Denitsa B., et al.
Publicado: (2021)

Combination of bortezomib and daunorubicin in the induction of apoptosis in T-cell acute lymphoblastic leukemia
por: Du, Xin, et al.
Publicado: (2017)

Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
por: El Khawanky, Nadia, et al.
Publicado: (2021)

MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
por: Bollaert, Emeline, et al.
Publicado: (2021)

High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials
por: Gong, Qiang, et al.
Publicado: (2015)

Reversal of multidrug resistance by magnetic Fe(3)O(4) nanoparticle copolymerizating daunorubicin and MDR1 shRNA expression vector in leukemia cells
por: Chen, Bao-an, et al.
Publicado: (2010)

Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia
por: Bae, Ki Hyun, et al.
Publicado: (2022)

Niosome: A future of targeted drug delivery systems
por: Kazi, Karim Masud, et al.
Publicado: (2010)

Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes
por: Davarpanah, Fereshteh, et al.
Publicado: (2018)

Rapid Microfluidic Preparation of Niosomes for Targeted Drug Delivery
por: Ag Seleci, Didem, et al.
Publicado: (2019)

Niosomes encapsulated in biohydrogels for tunable delivery of phytoalexin resveratrol
por: Machado, Noelia D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jd6oah952dup4255m4fcnojdg8